Cerevance raises another $5 mln
The Dementia Discovery Fund, which is managed by SV Life Sciences, has invested $5 million in the initial financing round of Cerevance. Cerevance, a drug discovery company with offices in Boston and Cambridge, U.K., has raised $36 million in commitments of equity and non-dilutive capital from Lightstone Ventures and Takeda Pharmaceuticals Co Ltd.
3 May 2017•3 mins read
